Annovis Bio's Buntanetap Found Safe and Effective in High-Risk Alzheimer's Patients

Core Insights - Annovis Bio Inc. announced significant efficacy and safety results from its Phase II/III Alzheimer's study of Buntanetap, showing improvements in both APOE4 carriers and non-carriers [1][2][3] Efficacy Findings - Buntanetap demonstrated a statistically significant dose-response in early Alzheimer's patients, with a -3.3 points improvement in ADAS-Cog11 scores over baseline and -2.3 points improvement from placebo [1] - In APOE4 carriers treated with 15mg Buntanetap, there was a -3.15 improvement in ADAS-Cog11 scores [2] Safety Profile - Buntanetap exhibited comparable safety in both APOE4 carriers and non-carriers, with no instances of Amyloid-Related Imaging Abnormalities (ARIA) reported [2][3] - The study included 159 APOE4 carriers (33 homozygotes and 126 heterozygotes) and 159 non-carriers, highlighting the diverse patient population [2] Scientific Context - Recent findings in Nature Medicine have redefined APOE4 homozygosity as a distinct genetic form of Alzheimer's, indicating a need for tailored prevention strategies and treatments [2] - Dr. Samuel Gandy noted the heightened safety risks associated with anti-amyloid drugs for APOE4 homozygotes, contrasting with Buntanetap's safety profile [3] Future Development Plans - Annovis Bio plans to initiate an 18-month Phase III trial focusing on biomarker-positive early Alzheimer's patients to further validate Buntanetap's efficacy and safety [4] - The upcoming investor call will provide detailed findings and outline future development plans for Buntanetap [4] Company Overview - Annovis Bio Inc. is dedicated to developing therapies for neurodegenerative diseases, targeting multiple neurotoxic proteins to restore brain function and improve patient quality of life [5]